EndoVia Therapeutics secures €344,050 in EIC Pre-Accelerator EU funding

EndoVia Therapeutics secured €344,050 in EIC Pre-Accelerator EU funding with support from Tiko Pro to advance PRECISION-ECS, its deep-tech precision oncology platform. The Horizon Europe funding will support technology validation, business development and investment readiness, helping the Slovenian startup prepare for future growth and opportunities such as the EIC Accelerator. 

Date: 1. 09. 2026

EndoVia Therapeutics has successfully secured €344,050 in EU funding through the EIC Pre-Accelerator for its PRECISION-ECS project, advancing an innovative deep-tech precision oncology platform for personalised cannabinoid-based cancer therapies. 

The Slovenian deep-tech startup received funding under the EIC Pre-Accelerator, a Horizon Europe funding scheme designed to strengthen the technology, business and investment readiness of promising deep-tech startups and SMEs in Horizon Europe widening countries. 

The successful application resulted in €344,050 in EIC Pre-Accelerator EU funding for the PRECISION-ECS project. 

The successful PRECISION-ECS application demonstrates how a strong scientific concept, a committed deep-tech team and professionally structured EU funding proposal development can create a competitive application for the EIC Pre-Accelerator. 

It also highlights the EU funding opportunities available to deep-tech startups and SMEs in Horizon Europe widening countries seeking to advance breakthrough technologies, strengthen their commercial and investment readiness and prepare for future programmes such as the EIC Accelerator. 

 

About the PRECISION-ECS project 

PRECISION-ECS aims to advance a precision oncology platform designed to predict, validate and personalise cannabinoid-based interventions in cancer treatment. 

The platform combines molecular tumour profiling, experimental validation and AI-powered digital twins to better predict how individual patients may respond to specific cannabinoid interventions. 

By integrating biological data with advanced computational modelling, EndoVia Therapeutics aims to support more evidence-based treatment decisions and help match the right cannabinoid intervention to the right patient. 

Through PRECISION-ECS, the company will further develop and validate its technology while strengthening its technology, business and investment readiness. The project represents an important step towards clinical application, commercialisation and the company's future scale-up. 

 

How Tiko Pro supported the successful EIC Pre-Accelerator application 

Tiko Pro provided end-to-end EU funding proposal preparation support, working closely with the EndoVia Therapeutics team throughout the application process. 

Our support included: 

  • Project concept refinement and EIC Pre-Accelerator call alignment – translating the innovation and development roadmap into a project concept aligned with the objectives and requirements of the funding scheme. 

  • Proposal development and structuring – developing and strengthening the proposal narrative and ensuring consistency between the scientific, technological, business and impact dimensions. 

  • Scientific and commercial positioning – clearly presenting the innovation, its technological potential, competitive advantages and commercial opportunity. 

  • Business case, impact and market positioning – strengthening the project's value proposition, expected impact, market perspective and pathway towards commercialisation and investment readiness. 

  • Coordination and submission preparation – coordinating the required inputs and preparing the application package for submission. 

  • Final quality review and submission support – performing a comprehensive final review and supporting the team through the final submission process. 

 

What is the EIC Pre-Accelerator? 

The EIC Pre-Accelerator is an EU funding instrument designed specifically for early-stage deep-tech startups and SMEs from Horizon Europe widening countries. 

Implemented within Horizon Europe through cooperation between the European Innovation Council (EIC) and the Widening Participation and Strengthening the European Research Area (WIDERA) programme, it aims to help promising deep-tech companies advance their technologies while strengthening their business and investment readiness. 

The programme addresses an important challenge for innovative companies in widening countries: promising deep-tech technologies may have strong scientific potential but still require further technological validation, commercial development and investment preparation before they are ready to compete for larger-scale European funding and private investment. 

 

About EndoVia Therapeutics 

EndoVia Therapeutics is a Slovenian deep-tech startup and spin-out from the University of Maribor developing a precision oncology platform that combines experimental biology and advanced computational modelling within a single workflow. 

The company evaluates defined cannabinoid and extract libraries against biological targets, validates predictions in subtype-specific tumour models and uses computational modelling to better understand individual patient responses. 

Its goal is to move cannabinoid oncology beyond trial-and-error approaches towards evidence-based, personalised treatment strategies that match the right intervention to the right patient. 

More about EndoVia Therapeutics: www.endovia.eu 

 

Review 

“Working with Tiko Pro on our EIC Pre-Accelerator application was an excellent experience. Their team showed strong expertise, responsiveness and a genuine commitment to our success. In the intensive period before submission, they were willing to work extended hours and adapt to our schedules, which we greatly appreciated. The lead consultant was highly skilled, proactive and dedicated, and their support significantly strengthened our proposal, which was ultimately selected for funding. For future projects, even more strategic input from senior team members would make an already very strong collaboration even better.” 

Dr. Jan Rožanc, Founder and CEO of EndoVia Therapeutics

Help
Increase your chances - contact us. Do you need help with EU funding? Contact us
E-novice

E-novice

Želite dvakrat na mesec prejemati uporabne novice iz področja pridobivanja financiranja?